What KS Nutripharma Delivers for Urolithin A Capsule Projects
| Manufacturing Model | OEM · ODM · Private Label |
| Dosage Form | Hard capsules (HPMC or gelatin shell) |
| Dose Range | 250 mg – 1000 mg active per serving, subject to formula feasibility |
| Capsule Sizes | #1 · #0 · #00, confirmed after fill-weight assessment |
| Formula Types | Single-ingredient or multi-ingredient (e.g., CoQ10, PQQ) |
| Raw Material Check | Identity, assay, bulk density, flowability, moisture, contaminants |
| Release Testing | Identity, assay, weight variation, disintegration, microbiological |
| Documentation | COA, specification sheet, test methods, regulatory docs per market |
| Production Scale | Pilot batch → commercial volume |
| Typical Lead Time | 4–6 weeks after formula and artwork confirmation |
| MOQ | Available upon project review |
Before any commercial batch, we run a trial blend to confirm fill weight, powder flow and capsule size feasibility.
Factory Overview:
| Metric | What It Means for Your Project |
| 19+ | Years in supplement manufacturing |
| 81,000 m² | Total manufacturing footprint |
| 5 | Production bases |
| 500+ | Brands served globally |
| 60+ | Export markets |
| cGMP/ISO/HACCP/FSSC 22000/HALAL/KOSHER | Certifications held |
Urolithin A Capsule Dosage Options
| Target Active per Serving | Typical Capsule Format | Manufacturing Considerations |
|---|---|---|
| 250 mg | 1 capsule | Lower fill requirement; fits #0 or #1 |
| 500 mg | 1–2 capsules | Common high-dose target; #0 typical starting point |
| 1000 mg | 2 capsules or custom config | Fill weight and serving size require feasibility review |
| Custom | Based on specification | Formula review required for assay, excipients and fill weight |
Work Process-From Raw Material to Finished Capsule
Identity verification against specification. Assay confirmation for dose calculation. Moisture, bulk density, flowability and contaminant screening (heavy metals, residual solvents, microbial limits). Documentation review: COA, specification sheet, test methods, allergen/GMO statements.
Target active dose is converted to raw material weight using the actual assay: Required raw material = Target active ÷ Assay. Example: 500 mg active ÷ 98% assay = ~510 mg raw material per serving (before excipients). Total fill weight determines capsule size (#1, #0 or #00).
A pilot blend is produced to verify powder flow, blend uniformity and fill-weight feasibility before any commercial batch is committed.
Hard capsule filling under GMP conditions. In-process monitoring: fill weight, capsule appearance, production parameters.
Identity and assay (Urolithin A content). Weight variation. Disintegration. Microbiological testing. Other customer-specific or market-required tests.
Batch release is issued against the agreed product specification—not a generic checklist. Release documentation includes COA, batch records and QC results.
Urolithin A Formula & Capsule Configuration
Urolithin A capsule configuration starts with the actual raw material specification, not the target active dose alone.
Urolithin A raw material may not be 100% active. The required input weight is calculated from the actual assay of the selected ingredient lot.
Required raw material = Target Urolithin A active amount ÷ Actual assay
For example:
500 mg target active ÷ 98% assay ≈ 510 mg Urolithin A raw material
This is the raw material input before adding excipients.
The final capsule fill weight is then determined by the complete blend, including the Urolithin A input, excipients, bulk density and processing requirements.
Capsule size is selected from the finished blend, not from the Urolithin A dose alone.
The formulation is evaluated in sequence:
Target active dose → Raw material assay → Required ingredient weight → Excipients → Bulk density & flowability → Total fill weight → Capsule size
This determines whether the target formula can be manufactured in a #1, #0 or #00 capsule, or whether multiple capsules per serving are more practical.
#1 Capsule
Suitable for lower-fill formulas where the total blend weight is relatively limited.
#0 Capsule
A practical starting point for many standard Urolithin A capsule formulations, subject to actual blend characteristics.
#00 Capsule
Used when the total fill weight is higher, such as higher-dose or multi-ingredient formulas.
Capsule size recommendations are indicative only. Final size is confirmed after evaluating the actual formulation blend.
Higher-dose and multi-ingredient formulas may require more than one capsule per serving when the total blend exceeds the practical capacity of a single capsule.
As a general development reference:
- 250 mg: often feasible in a single capsule, depending on the finished blend
- 500 mg: may be configured as one or two capsules depending on fill weight
- 1000 mg: commonly requires multiple capsules or a higher-capacity configuration
The final serving configuration is confirmed after formula and fill-weight assessment.
HPMC Capsules
Plant-derived shells commonly selected for vegan and vegetarian product positioning.
Gelatin Capsules
Traditional animal-derived shells commonly used for conventional supplement products and cost-sensitive formulations.
Final shell selection depends on the target market, product positioning, formulation requirements and commercial cost target.
Before Commercial Production
A trial blend can be used to verify fill weight, powder flow, blend uniformity and capsule-size feasibility before moving into commercial production.
Ready-to-Adapt Urolithin A Capsule Formula Concepts
Urolithin A capsules can be developed as single-ingredient products or combined with established actives used across healthy aging, mitochondrial wellness, longevity and active-aging categories.
The following are reference formulation concepts for commercial product development. Dosages can be adjusted according to raw material specifications, capsule capacity, target market, product positioning and cost requirements.
The concepts are designed to shorten the formulation development stage. Your team can select a starting formula and adjust:
- Urolithin A dose
- Secondary active dosage
- Raw material specifications
- Excipients
- Capsule size
- Capsules per serving
- HPMC or gelatin shell
- Bottle or blister packaging
- Target cost and production volume
Before pilot production, the final formula is reviewed for assay-based input calculation, total fill weight, powder flow, blend uniformity, capsule capacity and applicable market requirements.
Suggested Formula
Urolithin A · 250–500 mg per serving
Product Positioning
A focused, single-ingredient formula built around Urolithin A as the primary active.
Best For
- Premium Urolithin A products
- Science-led supplement brands
- Healthy-aging portfolios
- Simple, transparent labels
Why It Works
The simplest formulation architecture with fewer compatibility variables and a clear product proposition.
Customization
Adjust active dose, capsule shell, capsule count, bottle size and packaging format according to the target market.
Suggested Formula
Urolithin A · 250–500 mg + CoQ10 · 50–200 mg
Product Positioning
A mainstream premium formula combining Urolithin A with the established mitochondrial and energy ingredient CoQ10.
Best For
- Healthy-aging products
- Mitochondrial wellness
- Daily energy formulas
- Premium wellness brands
Why It Works
CoQ10 has strong market familiarity, making this a relatively accessible way to build a multi-active Urolithin A product.
Formulation Consideration
CoQ10 raw material characteristics can affect powder flow and capsule filling. Ingredient form, assay and excipient selection should be reviewed during formulation.
How We Evaluate
| Factor | Assessment |
|---|---|
| Moisture exposure | Finished blend sensitivity; whether additional moisture protection is needed |
| Temperature & storage | Target market, transportation and recommended storage conditions |
| Light & oxygen | Relevant to formulation and packaging specification |
| Excipient compatibility | Complete formulation evaluated, not Urolithin A in isolation |
| Target shelf life | Determines stability evidence and packaging performance required |
Packaging Options
Stability Evaluation
- Urolithin A assay
- Appearance and physical characteristics
- Moisture-related parameters
- Microbiological quality
- Packaging compatibility
How We Determine Final Packaging
Formula & Raw Material Specification
↓
Moisture / Environmental Risk Assessment
↓
Packaging Configuration
↓
Finished-Product Stability Evaluation
↓
Shelf-Life SpecificationWhat Human Research Has Examined
- Safety and tolerability
- Pharmacokinetics
- Mitochondrial-related biomarkers
- Muscle-related outcomes
- Physical performance
U.S. Regulatory Considerations
GRAS is not FDA approval.
- Ingredient specification
- Intended use
- Finished-product formulation
- Serving level
- Product category
- Label claims
- Target market
EU Market Considerations
Product Claims & Compliance
Manufacturing cost and lead time depend on the final product specification, not Urolithin A dosage alone.
What Affects Manufacturing Cost?
| Factor | How It Affects Your Project |
|---|---|
| Raw material specification | Assay affects the amount of raw material required. Commercial cost also depends on grade, supplier, purchasing volume and required documentation. |
| Formula complexity | Single-ingredient vs. multi-ingredient formulas can affect procurement, blending, testing and stability requirements. |
| Active dose & fill weight | Higher active loading increases raw material consumption and may increase capsule size or capsules per serving. |
| Capsule shell | HPMC and gelatin have different material costs and market-positioning implications. |
| Packaging | Stock formats can simplify procurement. Custom bottles, printed components or custom blister structures may require additional tooling, MOQs or approval steps. |
| Testing & documentation | Additional identity, assay, contaminant, microbiological, stability or market-specific testing may add cost and processing time. |
| Order volume | Affects raw material purchasing, packaging quantities, production efficiency and unit economics. |
What Affects Lead Time?
| Factor | Impact |
|---|---|
| Formula & specification confirmation | Incomplete formulas or changing specifications can delay development. |
| Raw material availability | Timing depends on whether the required Urolithin A grade and other ingredients are available in the required quantity. |
| Sample & trial development | Custom formulas may require trial blending and capsule-fill verification before commercial production. |
| Packaging & artwork | Custom packaging, artwork revisions and label approval can extend the project timeline. |
| Testing & release | Required finished-product testing must be completed before batch release. |
| Production scheduling | Commercial production timing depends on batch requirements, production capacity and the confirmed manufacturing schedule. |
Typical Commercial Timeline
Project & Specification Review
↓
Formula & Raw Material Confirmation
↓
Sample / Trial Development — if required
↓
Packaging & Artwork Approval
↓
Commercial Production
↓
Finished Product Testing & Release
Typical commercial lead time is approximately 4–6 weeks after formula, specifications, packaging and artwork are confirmed, subject to raw material availability, testing requirements and production scheduling.
Request a Urolithin A Capsule Manufacturing Quote
Send us your target Urolithin A dose, formula concept, order quantity, packaging requirements and target market.
Our team will review the formulation and capsule configuration, identify any key manufacturing considerations and prepare a project quotation based on the confirmed specification.
Information to Include
Product Specification
- Target Urolithin A dosage
- Capsules per serving
- Single-ingredient or multi-ingredient formula
- HPMC / gelatin / undecided
Formula & Technical Requirements
- Existing formula or formulation support required
- Capsule size — if known
- Existing raw material specification or COA — if available
- Special testing or documentation requirements
Commercial Requirements
- Target order quantity
- Packaging format
- Target market / sales region
- Desired launch timeline, if applicable
Don’t Have a Finalized Formula?
That’s fine.
You can start with the information you already have, such as:
500 mg Urolithin A + capsules + 10,000 bottles + U.S. market
We can then review the formula feasibility, capsule configuration, testing requirements and packaging options before finalizing the manufacturing quotation.
Custom dosages are feasible based on formula review. Common manufacturing targets include 250 mg, 500 mg and 1000 mg active per serving, subject to raw material assay and capsule fill-weight capacity.
Yes. 500 mg is a common manufacturing target, typically using #0 capsules. 1000 mg may require multiple capsules or #00, confirmed after fill-weight feasibility assessment.
Yes. Multi-ingredient formulas are supported, subject to compatibility and stability assessment during formula development.
We provide COA, specification sheets, test methods, allergen statements, GMO statements and other agreed documents. Finished-product testing includes identity, assay, weight variation, disintegration and microbiological testing per the approved specification.
Capsule size is determined by total fill weight, which depends on active dose, raw material assay, excipients and bulk density. We confirm this through trial blending before production.
MOQ depends on formula complexity, packaging type and order volume. Lead time is typically 4–6 weeks after formula and artwork confirmation, subject to raw material availability and testing requirements.
Target dose, capsule type, serving size, formula requirements, target quantity, packaging format, target market, and whether you need formulation support.
